When GLP-1 drugs have recently become a trendy dialogue point on impressive weight loss efficacy, we focus on the low appeal, especially the stomach side effects.
There are all nausea, vomiting, diarrhea, constipation and abdominal pain low Novo Nordisk’s WEGOVY (Semaglutide) and ELI LILLY’s Zepbound (Tirzepatide) reported. In fact, the real world research These GI side effects indicate that 40-70%of GLP-1 treatment patients.
Based on the interruption rate, the company’s concern is the company, drug developers and practitioners to maintain the worst of these side effects to maintain the drug and benefit from the serious weight loss generated by the public injection.
A Recent investigation 94%of the 50 doctors conducted by DNB Markets and Back Bay Life Science Advisors have evaluated the benefit safety profile as one of the most important factors in prescribing weight loss drugs.
The doctor seems to demand drugs with less side effects. Peter Bak, BACK BAY LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE LIFE Science Advisors Partners and Executive Directors, Sayed Bio space transmission. Prudent or capacity adjustment, updates or combinations, and drugs that target drugs are all strategies disposed to improve the taste of GLP-1.
In the case of David Cummings, the head of the weight management program of VA PUGET SOUND HELLTH CARE SYSTEM, side effects are not a decisive factor. “For my patients (camouflage side effects) are not a big deal, but it’s not a trivial deal.” Bio Space.
Proper, combination and secondary drugs
Side effects such as nausea and constipation are “easy to understand” regarding the mechanism of action of the drug, Cummings explained. One way to make the GLP-1 fill the patient is to slow the GI motility. If the drug affects the upper GI system too much, it can cause nausea as it occurs when you eat too quickly. If the drug has a strong impact on the lower level, the slow GI mobility leads to constipation, he said.
Cummings said, “In both cases, it is only a drug to do, and the appropriate response is to reduce the dose to a level that is still effective but low in side effects. Interestingly, he said there were researchers. uncertain Why diarrhea occurs with GLP-1 treatment.
The main strategy deployed by drug developers is appropriate to improve side effects. Departure capacity and maintenance time are important for optimizing patient instrumentation. Bio space.
Another popular approach is the union formula. Coll, like the formulation of the Zepbound, said that the addition of inhibitory polypeptide (GIP) or amylin receptor agent can alleviate the gastrointestinal effects led by GLP-1.
Amylin It has become a hot mechanism for the company’s favorite weight loss drug developer. Novo,,, structure,,, Astra Geneca and Viking drug Chase after the candidate’s approval.
Still, other companies are aiming for side effects of GLP-1 as a separate secondary drug.
In January, Jaguar Health subsidiary NAPO PHARMACEUTICALS is A Patent application If MyTesi treats common GI side effects with GIP treatment used in GLP-1 and obesity.
MyTesi is a vegetable oral drug that has already been approved for HIV -related diarrhea that shows additional advantages to abdominal pain, inconvenience, bloating and constipation when studied in HIV, irritable bowel syndrome (IBS) and cancer therapy.
CumMings is especially familiar with MyTesi, but if the drug truly helps to treat GLP-1 side effects, “I’ll definitely consider using it.”
But I am not sure Ben Urick, the chief director of the health results of Prime Therapeutics. He said Bio space Clinical goals are usually to find alternative treatment with side effects with less side effects.
Urick, a pharmacist, said, “We must really be sure we need other drugs. He added that patients with serious illnesses and no other choices can be useful.
GLP-1 interruption is all personality
Despite these extensive efforts, the jury is still out of how much problems with GLP-1-related side effects are. Cummings mentioned that only about 5%of GLP-1 drug patients actually have a problem with side effects.
A series of real worlds research Due to the side effects, patients taking semaglu tides for about 30 weeks will find a 5%interruption rate and reflect this claim.
Another real world studyAnnounced by Prime Therapeutics in July 2024, 85%of patients were no longer taking GLP-1 drugs two years after treatment. But this is not due to the adverse problem. Urick said that the interruption can be due to the five general causes, and the side effects are only one with economic, availability, doctor drug switches and weight loss targets.
But Urick added, “I don’t think the tribe has a big impact as I thought.”
Even in spite of literature When GLP-1 is promoted as long-term treatment, the prescribers point out that the patient often uses drugs to reach certain weight loss targets and stop treatment. Another indicator of this phenomenon is that in the study of Prime, patients without type 2 diabetes stop treatment at higher speed than patients with disease.
Urick also stated that Prime’s research data began in 2021 and the duration of treatment dropped to 15%, including old products that were no longer used. Urick said that the two -year sustainability will be nearly 25%through the “more modern product mix” led by heavy batters such as Zepbound and WEGOVY.
It does not say that side effects are not a problem for the patient. In fact, I think Urick has achieved the role of side effects and weight loss targets to identify the cause of GLP-1 interruption. The study was not designed to measure this, but the additional probe to Prime’s data revealed that people who persisted in treatment had lower side effects than those who stopped GLP-1. For Urick, this is a sign that side effects are associated with stopping drugs early. “There is a relationship between the two,” he said.
Ultimately, Coll said: “I don’t think there is a silver bullet that can continue to benefit from GLP-1 while completely eliminating all GI events.” He repeated emphasis on combination with GIP and amylin to optimize the drug. “That’s how we look at the future.”
